Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Open Access
- 2 November 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 21 (12), 1450-1460
- https://doi.org/10.1634/theoncologist.2015-0084
Abstract
Lung cancer remains the leading cause of cancer‐related deaths worldwide. However, significant progress has been made individualizing therapy based on molecular aberrations (e.g., EGFR, ALK) and pathologic subtype. KRAS is one of the most frequently mutated genes in non‐small cell lung cancer (NSCLC), found in approximately 30% of lung adenocarcinomas, and is thus an appealing target for new therapies. Although no targeted therapy has yet been approved for the treatment of KRAS‐mutant NSCLC, there are multiple potential therapeutic approaches. These may include direct inhibition of KRAS protein, inhibition of KRAS regulators, alteration of KRAS membrane localization, and inhibition of effector molecules downstream of mutant KRAS. This article provides an overview of the KRAS pathway in lung cancer and related therapeutic strategies under investigation. Implications for Practice: The identification of oncogene‐addicted cancers and specific inhibitors has revolutionized non‐small cell lung cancer (NSCLC) treatment and outcomes. One of the most commonly mutated genes in adenocarcinoma is KRAS, found in approximately 30% of lung adenocarcinomas, and thus it is an appealing target for new therapies. This review provides an overview of the KRAS pathway and related targeted therapies under investigation in NSCLC. Some of these agents may play a key role in KRAS‐mutant NSCLC treatment in the future.Keywords
This publication has 132 references indexed in Scilit:
- Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated ActivationAngewandte Chemie, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- An orthosteric inhibitor of the Ras-Sos interactionNature Chemical Biology, 2011
- Requirement for NF-κB signalling in a mouse model of lung adenocarcinomaNature, 2009
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras OncogeneCell, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- GEFs and GAPs: Critical Elements in the Control of Small G ProteinsCell, 2007
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005